68353
document
Sulforaphane treatment of autism spectrum disorder ( ASD ) . Autism spectrum disorder ( ASD ) , characterized by both impaired communication and social interaction , and by stereotypic behavior , affects about 1 in 68 , predominantly males . The medico-economic burdens of ASD are enormous , and no recognized treatment targets the core features of ASD . In a placebo-controlled , double-blind , randomized trial , young men ( aged 13-27 ) with moderate to severe ASD received the phytochemical sulforaphane ( n = 29 ) -- derived from broccoli sprout extracts -- or indistinguishable placebo ( n = 15 ) . The effects on behavior of daily oral doses of sulforaphane ( 50-150 µmol ) for 18 wk , followed by 4 wk without treatment , were quantified by three widely accepted behavioral measures completed by parents/caregivers and physicians : the Aberrant Behavior Checklist ( ABC ) , Social Responsiveness Scale ( SRS ) , and Clinical Global Impression Improvement Scale ( CGI-I ) . Initial scores for ABC and SRS were closely matched for participants assigned to placebo and sulforaphane . After 18 wk , participants receiving placebo experienced minimal change ( < 3.3 % ) , whereas those receiving sulforaphane showed substantial declines ( improvement of behavior ) : 34 % for ABC ( P < 0.001 , comparing treatments ) and 17 % for SRS scores ( P = 0.017 ) . On CGI-I , a significantly greater number of participants receiving sulforaphane had improvement in social interaction , abnormal behavior , and verbal communication ( P = 0.015-0.007 ) . Upon discontinuation of sulforaphane , total scores on all scales rose toward pretreatment levels . Dietary sulforaphane , of recognized low toxicity , was selected for its capacity to reverse abnormalities that have been associated with ASD , including oxidative stress and lower antioxidant capacity , depressed glutathione synthesis , reduced mitochondrial function and oxidative phosphorylation , increased lipid peroxidation , and neuroinflammmation .
68354
Intervention_Pharmacological
Sulforaphane
68355
Intervention_Pharmacological
phytochemical sulforaphane
68356
Intervention_Pharmacological
broccoli sprout extracts
68357
Intervention_Control
indistinguishable placebo
68358
Intervention_Pharmacological
sulforaphane
68359
Outcome_Mental
physicians : the Aberrant Behavior Checklist ( ABC )
68360
Outcome_Mental
Social Responsiveness Scale ( SRS )
68361
Outcome_Mental
Clinical Global Impression Improvement Scale ( CGI-I )
68362
Outcome_Other
Initial scores for ABC and SRS
68363
Outcome_Other
for SRS
68364
Outcome_Mental
in social interaction
68365
Outcome_Mental
abnormal behavior
68366
Outcome_Mental
verbal communication
68367
Outcome_Physical
including oxidative stress and lower antioxidant capacity
68368
Outcome_Physical
depressed glutathione synthesis
68369
Outcome_Other
reduced mitochondrial function and oxidative phosphorylation
68370
Outcome_Other
increased lipid peroxidation , and neuroinflammmation
68371
Participant_Sex
predominantly males
68372
Participant_Age
young
68373
Participant_Sex
men
68374
Participant_Age
( aged 13-27
68375
Participant_Condition
moderate to severe ASD
68376
Participant_Condition
participants receiving sulforaphane